66 related articles for article (PubMed ID: 14750508)
1. Naltrexone and nicotine patch smoking cessation: a preliminary study.
Krishnan-Sarin S; Meandzija B; O'Malley S
Nicotine Tob Res; 2003 Dec; 5(6):851-7. PubMed ID: 14750508
[TBL] [Abstract][Full Text] [Related]
2. Effects of naltrexone on smoking cessation outcomes and weight gain in nicotine-dependent men and women.
King AC; Cao D; O'Malley SS; Kranzler HR; Cai X; deWit H; Matthews AK; Stachoviak RJ
J Clin Psychopharmacol; 2012 Oct; 32(5):630-6. PubMed ID: 22926596
[TBL] [Abstract][Full Text] [Related]
3. Systematic review and meta-analysis of opioid antagonists for smoking cessation.
David SP; Chu IM; Lancaster T; Stead LF; Evins AE; Prochaska JJ
BMJ Open; 2014 Mar; 4(3):e004393. PubMed ID: 24633528
[TBL] [Abstract][Full Text] [Related]
4. Varying nicotine patch dose and type of smoking cessation counseling.
Jorenby DE; Smith SS; Fiore MC; Hurt RD; Offord KP; Croghan IT; Hays JT; Lewis SF; Baker TB
JAMA; 1995 Nov; 274(17):1347-52. PubMed ID: 7563558
[TBL] [Abstract][Full Text] [Related]
5. Nicotine replacement therapy.
Molyneux A
BMJ; 2004 Feb; 328(7437):454-6. PubMed ID: 14976103
[No Abstract] [Full Text] [Related]
6. A telephone-based support program for over-the-counter nicotine patch users.
Reid RD; Pipe AL
Can J Public Health; 1999; 90(6):397-8. PubMed ID: 10680265
[No Abstract] [Full Text] [Related]
7. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system.
Berrendero F; Robledo P; Trigo JM; Martín-García E; Maldonado R
Neurosci Biobehav Rev; 2010 Nov; 35(2):220-31. PubMed ID: 20170672
[TBL] [Abstract][Full Text] [Related]
8. High international electronic cigarette use among never smoker adolescents.
Dutra LM; Glantz SA
J Adolesc Health; 2014 Nov; 55(5):595-7. PubMed ID: 25344030
[No Abstract] [Full Text] [Related]
9. Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery.
Yerramreddy TR; Milewski M; Penthala NR; Stinchcomb AL; Crooks PA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3280-3. PubMed ID: 20451376
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the reinforcing effects of nicotine: a tribute to Nadia Chaudhri.
Sved AF; Caggiula AR; Donny EC
Psychopharmacology (Berl); 2023 Mar; 240(3):417-430. PubMed ID: 36329195
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.
Ray LA; Green R; Enders C; Leventhal AM; Grodin EN; Li G; Lim A; Hartwell E; Venegas A; Meredith L; Nieto SJ; Shoptaw S; Ho D; Miotto K
Am J Psychiatry; 2021 Sep; 178(9):818-828. PubMed ID: 34080890
[TBL] [Abstract][Full Text] [Related]
12. Endogenous opioid system: a promising target for future smoking cessation medications.
Norman H; D'Souza MS
Psychopharmacology (Berl); 2017 May; 234(9-10):1371-1394. PubMed ID: 28285326
[TBL] [Abstract][Full Text] [Related]
13. Smokers' Treatment Expectancies Predict Smoking Cessation Success.
Fucito LM; Toll BA; Roos CR; King AC
J Smok Cessat; 2016 Sep; 11(3):143-149. PubMed ID: 27594921
[TBL] [Abstract][Full Text] [Related]
14. A gene-by-sex interaction for nicotine reward: evidence from humanized mice and epidemiology.
Bernardi RE; Zohsel K; Hirth N; Treutlein J; Heilig M; Laucht M; Spanagel R; Sommer WH
Transl Psychiatry; 2016 Jul; 6(7):e861. PubMed ID: 27459726
[TBL] [Abstract][Full Text] [Related]
15. Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial.
Mooney ME; Schmitz JM; Allen S; Grabowski J; Pentel P; Oliver A; Hatsukami DK
Clin Pharmacol Ther; 2016 Oct; 100(4):344-52. PubMed ID: 27213949
[TBL] [Abstract][Full Text] [Related]
16. Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers.
Roche DJ; Ray LA; Yardley MM; King AC
Curr Addict Rep; 2016 Mar; 3(1):125-137. PubMed ID: 27162709
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers.
Yardley MM; Mirbaba MM; Ray LA
CNS Drugs; 2015; 29(10):833-45. PubMed ID: 26507831
[TBL] [Abstract][Full Text] [Related]
18. The opioid receptors as targets for drug abuse medication.
Noble F; Lenoir M; Marie N
Br J Pharmacol; 2015 Aug; 172(16):3964-79. PubMed ID: 25988826
[TBL] [Abstract][Full Text] [Related]
19. Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.
Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
Am J Drug Alcohol Abuse; 2015 Jan; 41(1):35-44. PubMed ID: 24949564
[TBL] [Abstract][Full Text] [Related]
20. Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.
Ray LA; Courtney KE; Ghahremani DG; Miotto K; Brody A; London ED
Psychopharmacology (Berl); 2014 Oct; 231(19):3843-53. PubMed ID: 24733235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
